Psilocybin might be effective for treatment-resistant depression even with ongoing SSRI use, study suggests

In a phase II clinical trial, a single dose of psilocybin, combined with SSRI treatment and supportive therapy, showed promising safety and therapeutic outcomes for individuals with treatment-resistant depression. While the results suggest that SSRIs do not inhibit the potential benefits of psilocybin therapy, the study’s open-label format and lack of a control group mean further research is necessary to confirm these findings.